In English | En español

National Cancer Institute

at the National Institutes of Health

NCI Home
Cancer Topics
Clinical Trials
Cancer Statistics
Research & Funding
News
About NCI

Clinical Trials Search Results

Page Options

Email This Document

Clinical Trial Questions?
Get Help:
1-800-4-CANCER
LiveHelp online chat

Popular Resources

Help Using the NCI Clinical Trials Search Form
How to Find a Cancer Treatment Trial
Learn About Clinical Trials
About NCI's List of Cancer Clinical Trials
NCI Dictionary of Cancer Terms
NCI Drug Dictionary
Featured Clinical Trials Supported by NCI

View Content for:

Patients
Health Professionals

Display:

Title
Description with: Locations Eligibility
Full Trial Description
Custom

Results 1-25 of 43 for your search:

Cancer Type/Condition:  BRCA2 mutation carrier
Stage/Subtype:  BRCA2 mutation carrier
Trial Status:  Active

Hide Search Criteria

Show Search Criteria

Help with Results

Select All on Page Sort by: Show Results per Page

National Screening in Denmark With MR Versus Mammography and Ultrasound of Women With BRCA1 or BRCA2 Mutations

Phase: Phase IV
Type: Screening
Status: Active
Age: 25 to 70
Sponsor: Other
Protocol IDs: DBCG07MRBRCA, NCT00413491

Letrozole in Preventing Breast Cancer in Postmenopausal Women With a BRCA1 or BRCA2 Mutation

Phase: Phase III
Type: Biomarker/Laboratory analysis, Prevention
Status: Active
Age: 40 to 69
Sponsor: Other
Protocol IDs: UC-0104/0701 - ONCO03, ONCO-03/0701, EU-20806, NOVARTIS-FNCLCC-ONCO 03/0701, 2007-000687-24, FNCLCC-ONCO-03/0701, FNCLCC-ONCO 03/0701 - LIBER, NCT00673335

Fenretinide in Healthy Young Women at Genetic and Familial Risk

Phase: Phase III
Type: Prevention
Status: Active
Age: 20 to 46
Sponsor: Other
Protocol IDs: IEO S462/109, 2009-010260-41, NCT01479192

Botulinum Toxin A (Botox) in Tissue Expander Breast Reconstruction

Phase: Phase III
Type: Supportive care
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: 11-001687, NCT01591746

High Dose Chemotherapy in Oligo-metastatic Homologous Recombination Deficient Breast Cancer

Phase: Phase III
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: N12OLG, 2012-000838-19, NCT01646034

Veliparib Monotherapy for Relapsed Ovarian Cancer With BRCA Mutation

Phase: Phase II, Phase I
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: Veli-BRCA, NCT01472783

Carboplatin or Docetaxel in Treating Women With Metastatic Genetic Breast Cancer. Note: The information about this trial has not been updated by the sponsor/principal investigator/lead organization. Cancer.gov cannot verify the accuracy of the information.

Phase: Phase II
Type: Treatment
Status: Active
Age: Not specified
Sponsor: Other
Protocol IDs: CRUK-BRCA-TRIAL, EUDRACT-2004-001496-20, EU-20603, ISRCTN43372330, BBC-CRUK-BRCA-TRIAL, NCT00321633

Prophylactic Irradiation to the Contralateral Breast for BRCA Mutation Carriers Undergoing Treatment for Breast Cancer

Phase: Phase II
Type: Prevention
Status: Active
Age: 30 to 90
Sponsor: Other
Protocol IDs: 102/07 (HT4351), NCT00496288

Rucaparib(CO-338;Formally Called AG-014699 or PF-0136738) in Treating Patients With Locally Advanced or Metastatic Breast Cancer or Advanced Ovarian Cancer

Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: CDR0000593558, CRUK-PH2-052, CRUK-PARP/BRCA, EU-20842, EUDRACT-2006-002348-27, PH2/052, NCT00664781

10.

S0812 High Dose Cholecalciferol in Premenopausal Women at High-Risk for Breast Cancer

Phase: Phase II
Type: Biomarker/Laboratory analysis, Prevention
Status: Active
Age: 18 to 50
Sponsor: NCI, Other
Protocol IDs: CDR0000668698, S0812, U10CA032102, SWOG-S0812, NCT01097278

11.

Prevention Strategy for Pre-Menopausal Women at High Risk for Development of Breast Cancer

Phase: Phase II
Type: Biomarker/Laboratory analysis, Prevention
Status: Active
Age: 21 to 49
Sponsor: Other
Protocol IDs: 12377, NCT01276704

12.

The Study Evaluating Efficacy And Tolerability Of Veliparib in Combination With Temozolomide or In Combination With Carboplatin and Paclitaxel Versus Placebo in Subjects With BRCA1 and BRCA2 Mutation and Metastatic Breast Cancer

Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: M12-895, 2011-002913-12, NCT01506609

13.

Gemcitabine Hydrochloride and Cisplatin With or Without Veliparib or Veliparib Alone in Patients With Locally Advanced or Metastatic Pancreatic Cancer

Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 18 and over
Sponsor: NCI
Protocol IDs: NCI-2012-00864, IRB#12-045, U01CA069856, MSKCC-12-045, 12-045, 8993, NCT01585805

14.

Veliparib in Treating Patients With Malignant Solid Tumors That Did Not Respond to Previous Therapy

Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 18 and over
Sponsor: NCI
Protocol IDs: NCI-2011-01472, UPCI # 08-121, CINJ-050810, CDR0000641433, U01CA099168, U01CA062505, 8282, NCT00892736

15.

ABT-888 and Gemcitabine Hydrochloride in Treating Patients With Advanced Solid Tumors

Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 18 and over
Sponsor: NCI
Protocol IDs: NCI-2011-01473, 09-012, U01CA099168, UPCI 09-012, 8324, NCT01154426

16.

A Trial Using Novel Markers to Predict Malignancy in Elevated-Risk Women

Phase: Phase I
Type: Biomarker/Laboratory analysis, Natural history/Epidemiology, Screening
Status: Active
Age: 25 to 80
Sponsor: Other
Protocol IDs: P50CA83636-01, 6973, NCT01121640

17.

Veliparib, Oxaliplatin, and Capecitabine in Treating Patients With Advanced Solid Tumors

Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 18 and over
Sponsor: NCI
Protocol IDs: NCI-2011-02543, C010903, CDR0000687938, U01CA062491, WCCC-CO-10903, CO10903, 8604, NCT01233505

18.

Olaparib in Combination With Carboplatin for Refractory or Recurrent Women's Cancers

Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 18 and over
Sponsor: NCI
Protocol IDs: 110022, 11-C-0022, NCT01237067

19.

Veliparib and Dinaciclib With or Without Carboplatin in Treating Patients With Advanced Solid Tumors

Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 18 and over
Sponsor: NCI
Protocol IDs: NCI-2011-03458, 11-144, U01CA062490, DFCI-11-144, 8484, NCT01434316

20.

Clinical Trial to Screen Participants Who Are at High Genetic Risk for Ovarian Cancer

Phase: No phase specified
Type: Screening
Status: Active
Age: 30 and over
Sponsor: NCI, Other
Protocol IDs: CDR0000069397, MGH-000084, NCT00039559

21.

The IMPACT Study - Identification of Men With a Genetic Predisposition to ProstAte Cancer

Phase: No phase specified
Type: Biomarker/Laboratory analysis, Screening
Status: Active
Age: 40 to 69
Sponsor: Other
Protocol IDs: 05/MRE07/25, CCR2598, NCT00261456

22.

Breast Cancer Risk Assessment Using Optical Breast Spectroscopy (OBS)

Phase: No phase specified
Type: Screening
Status: Active
Age: Not specified
Sponsor: Other
Protocol IDs: UHNREB#07-0689-CE, HC#124313, NCT00500383

23.

Outcomes of a DIEP Flap Program

Phase: No phase specified
Type: Health services research, Supportive care
Status: Active
Age: 20 to 70
Sponsor: Other
Protocol IDs: 2007-P-000232/1, NCT00543907

24.

Studying Breast Cancer Risk in Women Who Are BRCA1/BRCA2 Mutation Carriers

Phase: No phase specified
Type: Biomarker/Laboratory analysis
Status: Active
Age: 18 to 80
Sponsor: NCI, Other
Protocol IDs: CDR0000598427, GOG-8008, NCT00897455

25.

Lysophosphatidic Acid Assay in Patients With Ovarian Cancer or Who Are at Risk for Ovarian Cancer. Note: The information about this trial has not been updated by the sponsor/principal investigator/lead organization. Cancer.gov cannot verify the accuracy of the information.

Phase: No phase specified
Type: Screening
Status: Active
Age: 21 and over
Sponsor: NCI
Protocol IDs: WIHRI-09-0030, 09-0030, NCT00986206

Select All on Page

Help with Results

We Can Answer Your Questions
1-800-4-CANCER
LiveHelp Online Chat

NCI Home
Contact Us
Policies
Accessibility
Viewing Files
FOIA
Site Help
Site Map